By InvitationNot Applicable

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

United States100 participantsStarted 2026-03-02

Plain-language summary

This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Individual with vestibular schwannoma who received an intracochlear administration of
✓Participant willingness to comply with all study requirements as evidenced by successful completion of the informed consent process.

Exclusion criteria

✕Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the study.

What they're measuring

Long term safety of AAVAnc80-antiVEGF, including late-occurring adverse events (AEs

Timeframe: Through study completion, approximately four years.

Trial details

NCT IDNCT07503613

SponsorAkouos, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2040-04

View on ClinicalTrials.gov More Vestibular Schwannoma trials